Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 18 5 2018
medline: 21 8 2019
entrez: 18 5 2018
Statut: ppublish

Résumé

To determine the outcomes of complete surgical resection of T4 prostate cancer after inductive androgen-deprivation therapy (ADT), as inductive ADT and subsequent radical prostatectomy (RP) is not recommended by any guideline yet. A monocentric RP database was queried for patients initially diagnosed with T4 prostate cancer, considered primarily as inoperable because of a fixed mass defined by rectal examination in combination with high PSA level and/or large foci of biopsy confirmed undifferentiated prostate cancer. Treatment consisted of primary ADT until PSA nadir with consecutive RP. Patients underwent retropubic RP (RRP) or robot-assisted laparoscopic RP (RALP) after inductive ADT until achievement of the PSA nadir, which is in general reached after 6-7 months. The intraoperative course and complications were analysed. Finally, Kaplan-Meier estimates were calculated for overall survival (OS) and prostate cancer-specific survival (PCSS). We retrospectively identified 116 patients treated between 2000 and 2014. At diagnosis, the median (range) PSA level was 37.6 (2.44-284) ng/mL. The preoperative median (range) PSA after inductive ADT was 0.73 (0.01-34) ng/mL. Thereafter, patients underwent RRP or, since 2006, RALP. The median (95% confidence interval) OS was 156 (118.9-193.1) months. The PCSS at 150 months was 82%. Surgical therapy of primarily inoperable prostate cancer is feasible and safe after inductive ADT. The OS of this cohort seems comparable with results described for patients with primary operable high-risk prostate cancer.

Identifiants

pubmed: 29772100
doi: 10.1111/bju.14393
doi:

Substances chimiques

Androgen Antagonists 0
Gonadotropin-Releasing Hormone 33515-09-2
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Pagination

58-64

Informations de copyright

© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.

Auteurs

Turkan Hajili (T)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Carsten H Ohlmann (CH)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Johannes Linxweiler (J)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Christina Niklas (C)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Martin Janssen (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Stefan Siemer (S)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Michael Stoeckle (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Matthias Saar (M)

Department of Urology and Pediatric Urology, Saarland University, Homburg/Saar, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH